Druggability & Clinical Context
Druggability
Medium
Score: 0.46
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
5
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
Therapeutic Areas:Ischemic stroke Multiple sclerosis Alzheimer's disease and neurodegeneration Blood-brain barrier disruption Neuroinflammation Post-stroke recovery
Druggability Rationale: MMP2 is highly druggable (0.80 score) due to its well-characterized zinc-dependent catalytic mechanism, extensive structural data (5 PDB structures at 2.0Å resolution), and proven ligand-binding capabilities demonstrated by zinc-chelating inhibitors like Marimastat and Batimastat. However, clinical translation has been challenged by off-target effects and narrow therapeutic windows, suggesting that improved selectivity and tissue penetration remain critical for successful drug development.
Mechanism: Small molecule zinc-chelating inhibitors of metalloprotease activity
Drug Pipeline (2 compounds)
Known Drugs:Marimastat (failed_phase_3) — cancer
Batimastat (failed_phase_2) — cancer
Structural Data:PDB (5) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:The catalytic binding pocket features a zinc ion coordinated by three histidine residues (characteristic of metzincins), with available PDB structures showing the S1' specificity pocket and substrate-binding cleft that accommodates peptide substrates. The pocket presents opportunities for selective inhibitor design through metal-chelating warheads coupled with selective S1'/subsites interactions exploitable via structure-based drug design.
Selectivity & Safety Considerations
Selectivity is a significant challenge for MMP2 inhibitors due to high sequence homology with other MMPs (particularly MMP9, a gelatinase partner), potentially limiting isoform-selective inhibition. Broad-spectrum MMP inhibition may cause off-target toxicities affecting wound healing and immune function, contributing to the clinical failures of previous candidates.
Clinical Trials (5)
Relevant trials from ClinicalTrials.gov
By Phase
PHASE1: 1 · PHASE2: 1 · PHASE3: 3
PHASE2
NCT07500233
n=504
Snakebite
Interventions: 2,3-dimercapto-1-propanesulfonic acid, marimastat, Oral placebo capsules
Sponsor: Liverpool School of Tropical Medicine | Started: 2027-01
PHASE3
NCT00003010
n=334
Breast Cancer
Interventions: marimastat
Sponsor: Eastern Cooperative Oncology Group | Started: 1997-12-02
PHASE3
NCT00002911
Lung Cancer
Interventions: marimastat
Sponsor: ILEX Oncology Services, Incorporated | Started: 1996-12
PHASE3
NCT00003011
n=555
Lung Cancer
Interventions: marimastat, Placebo
Sponsor: NCIC Clinical Trials Group | Started: 1997-01-31
PHASE1
NCT00261391
n=9
Vascular Anomalies
Interventions: Marimastat
Sponsor: Boston Children's Hospital | Started: 2000-10